InMune Bio (INMB.US) skyrocketed before the market! Preliminary data for early Alzheimer's trials with drug candidate XPro will be released next week

The Zhitong Finance App learned that clinical-stage biotechnology company InMune Bio (INMB.US) said it will hold a conference call at 8 a.m. EST on June 30 to release preliminary data from the Mindful Phase II trial of its drug candidate XPro to treat early-stage Alzheimer's disease (AD). The market responded positively to this news. As of press release, InMune Bio's US stock surged more than 56% at the beginning of the session on Friday.

According to the data, xPro is a tumor necrosis factor (TNF) inhibitor. Unlike TNF inhibitors currently on the market, xPro specializes in soluble TNF and does not affect transmembrane TNF or TNF receptors, thereby helping to reduce neuroinflammation in diseases such as Alzheimer's.

The Mindful trial has enrolled 208 patients diagnosed with mild cognitive impairment (MCI) or mild AD, with an average age of 72 years. The primary end point of the trial was the change in cognitive score relative to baseline, measured by the Early and Mild Alzheimer's Disease Comprehensive Cognitive Score (EMACC), a tool designed to objectively measure the results of early AD clinical trials.